Not a good buy right now for an impatient entry: price is extended after a sharp +4.25% move and is pushing into near-term resistance (R2 ~160), raising near-term pullback/consolidation risk.
Medium-term trend and fundamentals are positive (bullish MAs, positive MACD, solid Q1 and upbeat FY outlook), so EMR remains a high-quality name—just not an attractive immediate entry after today’s surge.
Options positioning is bullish (low put/call ratios + volume spike), but elevated IV percentile suggests the market is already pricing in big moves, reducing the edge for fresh entries at this moment.
Pattern-based forward odds (similar candlesticks): ~50% chance of +1.21% next day, +1.81% next week, +1.42% next month (edge is modest, not a strong “must-buy-now” setup).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Bullish skew—puts are relatively light vs calls (OI P/C 0.49; Volume P/C 0.27).
Activity: Today’s option volume is very elevated (today vs 30-day avg ~261%), consistent with heightened bullish interest/positioning.
Volatility: 30D IV ~26.13 vs HV ~27 (roughly in-line), but IV percentile is high (76.1) → options are priced “richer” vs recent history.
Takeaway: Options market is leaning bullish, but the stock’s short-term stretch + elevated IV reduces the attractiveness of chasing at this exact level.
Net income: $605M, +3.42% YoY (profit growth positive but not accelerating sharply).
EPS: $1.07, +4.90% YoY.
Gross margin: 53.18%, up ~10.68% YoY (notable margin expansion, a key quality signal).
Overall: Healthy growth + improving margins supports the longer-term bull case, but doesn’t eliminate near-term overbought timing risk at today’s price.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Price targets have generally moved up post-results, but ratings are mixed with valuation-driven caution.
Bullish/pro: Citi reiterated Buy and raised PT to $174; UBS upgraded to Buy with $168 PT (sees upside from underlying demand/estimate revisions).
Neutral/cautious: JPMorgan Neutral PT $157; Wells Fargo Equal Weight PT raised to $160 (focus on order KPI and guide sensitivity).
Bearish: Morgan Stanley remains Underweight (PT $125).
Wall Street “pros vs cons”: Pros—order momentum, margin profile, shareholder returns, potential estimate revisions. Cons—valuation/limited near-term upside after the run, and sensitivity to order trajectory/second-half delivery.
Wall Street analysts forecast EMR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMR is 150.46 USD with a low forecast of 125 USD and a high forecast of 170 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast EMR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EMR is 150.46 USD with a low forecast of 125 USD and a high forecast of 170 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
6 Hold
1 Sell
Moderate Buy
Current: 150.940
Low
125
Averages
150.46
High
170
Current: 150.940
Low
125
Averages
150.46
High
170
Evercore ISI
NULL
to
Outperform
maintain
$170 -> $185
AI Analysis
2026-02-05
New
Reason
Evercore ISI
Price Target
$170 -> $185
AI Analysis
2026-02-05
New
maintain
NULL
to
Outperform
Reason
Evercore ISI raised the firm's price target on Emerson to $185 from $170 and keeps an Outperform rating on the shares, citing accelerating orders following the company's earnings report.
KeyBanc
NULL -> Overweight
maintain
$155 -> $185
2026-02-05
New
Reason
KeyBanc
Price Target
$155 -> $185
2026-02-05
New
maintain
NULL -> Overweight
Reason
KeyBanc raised the firm's price target on Emerson to $185 from $155 and keeps an Overweight rating on the shares following quarterly results. The firm was encouraged by Emerson's solid Q1 2026 organic order growth, which it thinks supports potential upside to FY27 estimates.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EMR
